Accrued Liabilities, Current in USD of Apellis Pharmaceuticals, Inc. from Q4 2016 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Summary
Apellis Pharmaceuticals, Inc. quarterly Accrued Liabilities, Current history and change rate from Q4 2016 to Q3 2025.
  • Apellis Pharmaceuticals, Inc. Accrued Liabilities, Current for the quarter ending 30 Sep 2025 was $140M, a 0.35% increase year-over-year.
Accrued Liabilities, Current, Quarterly (USD)
Accrued Liabilities, Current, YoY Quarterly Change (%)

Apellis Pharmaceuticals, Inc. Quarterly Accrued Liabilities, Current (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $140M +$487K +0.35% 30 Sep 2025 10-Q 30 Oct 2025
Q2 2025 $139M +$16.2M +13.2% 30 Jun 2025 10-Q 31 Jul 2025
Q1 2025 $116M +$14.7M +14.5% 31 Mar 2025 10-Q 07 May 2025
Q4 2024 $140M +$12.4M +9.69% 31 Dec 2024 10-Q 30 Oct 2025
Q3 2024 $140M +$22.7M +19.4% 30 Sep 2024 10-Q 05 Nov 2024
Q2 2024 $123M +$25.1M +25.7% 30 Jun 2024 10-Q 01 Aug 2024
Q1 2024 $101M +$30.1M +42.3% 31 Mar 2024 10-Q 07 May 2024
Q4 2023 $128M +$32.7M +34.3% 31 Dec 2023 10-K 28 Feb 2025
Q3 2023 $117M +$37.3M +46.8% 30 Sep 2023 10-Q 01 Nov 2023
Q2 2023 $97.7M +$8.3M +9.28% 30 Jun 2023 10-Q 31 Jul 2023
Q1 2023 $71.3M -$34M -32.3% 31 Mar 2023 10-Q 04 May 2023
Q4 2022 $95.1M -$8.1M -7.85% 31 Dec 2022 10-K/A 29 Feb 2024
Q3 2022 $79.8M +$9.93M +14.2% 30 Sep 2022 10-Q 07 Nov 2022
Q2 2022 $89.4M -$44.9M -33.4% 30 Jun 2022 10-Q 08 Aug 2022
Q1 2022 $105M +$35.9M +51.7% 31 Mar 2022 10-Q 04 May 2022
Q4 2021 $103M -$8.7M -7.77% 31 Dec 2021 10-K 21 Feb 2023
Q3 2021 $69.8M +$9.08M +14.9% 30 Sep 2021 10-Q 08 Nov 2021
Q2 2021 $134M +$88.9M +196% 30 Jun 2021 10-Q 09 Aug 2021
Q1 2021 $69.4M +$24.5M +54.5% 31 Mar 2021 10-Q 28 Apr 2021
Q4 2020 $112M +$57.2M +104% 31 Dec 2020 10-K 28 Feb 2022
Q3 2020 $60.8M +$30.3M +99.7% 30 Sep 2020 10-Q 02 Nov 2020
Q2 2020 $45.4M +$25.2M +124% 30 Jun 2020 10-Q 30 Jul 2020
Q1 2020 $44.9M +$37.6M +512% 31 Mar 2020 10-Q 29 Apr 2020
Q4 2019 $54.8M +$49.7M +974% 31 Dec 2019 10-K 25 Feb 2021
Q3 2019 $30.4M +$19.9M +188% 30 Sep 2019 10-Q 05 Nov 2019
Q2 2019 $20.2M +$15.1M +295% 30 Jun 2019 10-Q 31 Jul 2019
Q1 2019 $7.34M +$4.63M +171% 31 Mar 2019 10-Q 07 May 2019
Q4 2018 $5.1M +$2.21M +76.5% 31 Dec 2018 10-K 27 Feb 2020
Q3 2018 $10.6M +$7.63M +260% 30 Sep 2018 10-Q 13 Nov 2018
Q2 2018 $5.12M 30 Jun 2018 10-Q 31 Jul 2018
Q1 2018 $2.71M 31 Mar 2018 10-Q 30 Apr 2018
Q4 2017 $2.89M +$1.8M +165% 31 Dec 2017 10-K 26 Feb 2019
Q3 2017 $2.94M 30 Sep 2017 10-Q 20 Dec 2017
Q4 2016 $1.09M 31 Dec 2016 10-K 19 Mar 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.